SHC
Sotera Health Co
$
16.600
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
16.660
Open
16.230
VWAP
16.54
Vol
1.28M
Mkt Cap
4.72B
Low
15.590
Amount
21.21M
EV/EBITDA(TTM)
14.17
Total Shares
283.07M
EV
6.70B
EV/OCF(TTM)
25.16
P/S(TTM)
4.21
Sotera Health Company is a global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. The Company’s segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
270.93M
+6.44%
0.163
+16.08%
305.62M
+5.31%
0.234
+11.34%
303.65M
+6.37%
0.218
+28.38%
Estimates Revision
The market is revising Downward the revenue expectations for Sotera Health Company (SHC) for FY2025, with the revenue forecasts being adjusted by -0.01% over the past three months. During the same period, the stock price has changed by 47.16%.
Revenue Estimates for FY2025
Revise Downward
-0.01%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+4.26%
In Past 3 Month
Stock Price
Go Up
+47.16%
In Past 3 Month
5 Analyst Rating
4.82% Upside
Wall Street analysts forecast SHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SHC is 17.40 USD with a low forecast of 14.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
4.82% Upside
Current: 16.600
Low
14.00
Averages
17.40
High
21.00
4.82% Upside
Current: 16.600
Low
14.00
Averages
17.40
High
21.00
Barclays
Luke Sergott
Overweight
maintain
$13 -> $17
2025-08-08
Reason
Barclays
Luke Sergott
Price Target
$13 -> $17
2025-08-08
maintain
Overweight
Reason
Barclays analyst Luke Sergott raised the firm's price target on Sotera Health to $17 from $13 and keeps an Overweight rating on the shares following the Q2 report. The firm believes the shares are undervalued on the core business but that Sotera's litigation overhang limits what investors are willing to pay.
Barclays
Overweight
maintain
$15 -> $13
2025-06-24
Reason
Barclays
Price Target
$15 -> $13
2025-06-24
maintain
Overweight
Reason
Barclays lowered the firm's price target on Sotera Health to $13 from $15 and keeps an Overweight rating on the shares as part of a Q2 preview for the life science and diagnostic tools sector. Sentiment on the group is shifting more positive on the notion that many of the unknown headwinds around policy changes, namely National Institutes of Health budgetary cuts and pharma tariffs, are likely to prove less severe than feared, the analyst tells investors in a research note. Barclays still favors businesses exposed to commercial and clinical volumes, mainly bioprocessing and diagnostics.
Piper Sandler
Jason Bednar
Hold
Maintains
$15 → $13
2025-04-23
Reason
Piper Sandler
Jason Bednar
Price Target
$15 → $13
2025-04-23
Maintains
Hold
Reason
Piper Sandler analyst Jason Bednar lowered the firm's price target on Becton Dickinson to $260 from $280 and keeps an Overweight rating on the shares ahead of quarterly results. The firm notes that policy and broad economic uncertainty has seemingly created opportunities for investors to do value shopping, with Becton Dickinson (BDX) and Sotera Health (SHC) looking best positioned to respond favorably to upcoming reports when considering current sentiment/positioning.
Barclays
Luke Sergott
Buy
Maintains
$16 → $12
2025-04-10
Reason
Barclays
Luke Sergott
Price Target
$16 → $12
2025-04-10
Maintains
Buy
Reason
Barclays analyst Luke Sergott lowered the firm's price target on Sotera Health to $12 from $16 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.
Barclays
Luke Sergott
Buy
Maintains
$17 → $16
2025-02-28
Reason
Barclays
Luke Sergott
Price Target
$17 → $16
2025-02-28
Maintains
Buy
Reason
Barclays
Luke Sergott
Buy
Maintains
$18 → $17
2025-02-18
Reason
Barclays
Luke Sergott
Price Target
$18 → $17
2025-02-18
Maintains
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Sotera Health Co (SHC.O) is 20.07, compared to its 5-year average forward P/E of 20.20. For a more detailed relative valuation and DCF analysis to assess Sotera Health Co 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
20.20
Current PE
20.07
Overvalued PE
26.32
Undervalued PE
14.09
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
12.79
Current EV/EBITDA
11.23
Overvalued EV/EBITDA
16.70
Undervalued EV/EBITDA
8.88
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Strongly Overvalued
5Y Average PS
4.73
Current PS
16.60
Overvalued PS
6.66
Undervalued PS
2.80
Financials
Annual
Quarterly
FY2025Q2
YoY :
+6.42%
294.34M
Total Revenue
FY2025Q2
YoY :
+15.14%
88.43M
Operating Profit
FY2025Q2
YoY :
-9.05%
7.96M
Net Income after Tax
FY2025Q2
YoY :
0.00%
0.03
EPS - Diluted
FY2025Q2
YoY :
+21.05%
23.45M
Free Cash Flow
FY2025Q2
YoY :
+7.61%
53.45
Gross Profit Margin - %
FY2025Q2
YoY :
+240.82%
10.02
FCF Margin - %
FY2025Q2
YoY :
-14.24%
2.71
Net Margin - %
FY2025Q2
YoY :
-154.42%
-2.34
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 23211.51% over the last month.
Sold
0-3
Months
483.6M
USD
3
3-6
Months
2.1M
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 140.83% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
6.6K
Volume
1
0-12
Months
76.4K
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
2
7.0M
Volume
Months
0-12
2
2.9M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 23211.51% over the last month.
Sold
0-3
Months
483.6M
USD
3
3-6
Months
2.1M
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SHC News & Events
Events Timeline
2025-09-04 (ET)
2025-09-04
09:01:08
Sotera Health's 20 Million Share Spot Secondary Offering Set at $15.35
2025-09-03 (ET)
2025-09-03
20:24:49
Sotera Health Plans Secondary Offering of 20 Million Shares at Price Range of $15.20 to $15.98
2025-09-03
16:58:56
Sotera Health Reveals $20 Million Common Stock Offering for Shareholders
Sign Up For More Events
Sign Up For More Events
News
4.0
10-02NASDAQ.COMSotera Health Achieves Analyst Price Target
8.0
09-19NASDAQ.COMInitial Week of SHC Options Trading for May 2026
4.5
08-18NASDAQ.COMMost Active Stocks in Pre-Market Trading on August 18, 2025: OPEN, TSLL, IQ, ETHA, SQQQ, INTC, NVO, NIO, UNH, BBAI, BAC, SHCO
Sign Up For More News
People Also Watch
GFF
Griffon Corp
74.010
USD
-1.03%
FROG
Jfrog Ltd
47.480
USD
+1.02%
SKT
Tanger Inc
32.560
USD
+0.56%
CXT
Crane NXT Co
63.250
USD
-1.50%
IAC
IAC Inc
32.220
USD
+1.26%
NPO
Enpro Inc
232.010
USD
+2.68%
VKTX
Viking Therapeutics Inc
38.080
USD
-0.24%
ASO
Academy Sports and Outdoors Inc
47.890
USD
+2.20%
KFY
Korn Ferry
64.700
USD
-1.06%
RUM
Rumble Inc
6.860
USD
+2.08%
FAQ
What is Sotera Health Co (SHC) stock price today?
The current price of SHC is 16.6 USD — it has increased 1.59 % in the last trading day.
What is Sotera Health Co (SHC)'s business?
What is the price predicton of SHC Stock?
What is Sotera Health Co (SHC)'s revenue for the last quarter?
What is Sotera Health Co (SHC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Sotera Health Co (SHC)'s fundamentals?
How many employees does Sotera Health Co (SHC). have?